Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram

By Iyo M.   Ying B.   Hashimoto K.   Inada T.   Fukui S.  

European Journal of Pharmacology, Vol. 312, Iss. 2, 1996-09 ,pp. : 163-170

Elsevier

Access to resources Recommend Favorite

Protection by a cyclic AMP-specific phosphodiesterase inhibitor, rolipram, and dibutyryl cyclic AMP against Propionibacterium acnes and lipopolysaccharide-induced mouse hepatitis

By Taguchi I.   Oka K.   Kitamura K.   Sugiura M.   Oku A.   Matsumoto M.  

Inflammation Research, Vol. 48, Iss. 7, 1999-07 ,pp. : 380-385

Springer Publishing Company

Access to resources Recommend Favorite

Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol

By Sasaki H.   Hashimoto K.   Inada T.   Fukui S.   Iyo M.  

European Journal of Pharmacology, Vol. 282, Iss. 1, 1995-08 ,pp. : 71-76

Elsevier

Access to resources Recommend Favorite

KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5

By Hirose R.   Okumura H.   Yoshimatsu A.   Irie J.   Onoda Y.   Nomoto Y.   Takai H.   Ohno T.   Ichimura M.  

European Journal of Pharmacology, Vol. 431, Iss. 1, 2001-11 ,pp. : 17-24

Elsevier

Access to resources Recommend Favorite

CI-966, a GABA Uptake Inhibitor, Antagonizes Ischemia-induced Neuronal Degeneration in the Gerbil

By Phillis J.W.  

General Pharmacology, Vol. 26, Iss. 5, 1995-09 ,pp. : 1061-1064

Elsevier

Access to resources Recommend Favorite